1.
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.
2.
3.
4.
5.
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.
6.
7.
8.
9.
Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.